Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Communication Of Fidaxomicin's 30-Day Effect Is Question For Labeling Discussions

This article was originally published in The Pink Sheet Daily

Executive Summary

Anti-Infective Drugs Advisory Committee votes 13-0 to approve the antibiotic for treating Clostridium difficile, but rejects a claim for lowering the risk of recurrence, preferring focus on effect at 30 days.

You may also be interested in...



Optimer Looking At Prophylaxis As Next Frontier For C. Difficile Agent Dificid

Optimer's next step, having garnered the expected FDA approval of its Clostridium difficile antibiotic Dificid (fidaxomicin), will be to consider prophylaxis as a possible road to an expanded market for the macrolide antibiotic.

Optimer Looking At Prophylaxis As Next Frontier For C. Difficile Agent Dificid

Optimer's next step, having garnered the expected FDA approval of its Clostridium difficile antibiotic Dificid (fidaxomicin), will be to consider prophylaxis as a possible road to an expanded market for the macrolide antibiotic.

Labeling For Optimer's Dificid Includes Data On Ability To Sustain Cure Post-Treatment

FDA approves the macrolide antibacterial for treatment of Clostridium difficile-associated diarrhea.

Related Content

Topics

UsernamePublicRestriction

Register

PS072190

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel